<DOC>
	<DOCNO>NCT01662700</DOCNO>
	<brief_summary>In Thailand , proportion P.vivax infection increase equal Plasmodium falciparum since 1998 . The incidence P.vivax recently report 20 per 1000 population per year . Unlike Plasmodium falciparum , P.vivax infection rarely develop complicate malaria death unusual . However , P.vivax dormant stage ( hypnozoite ) persist human liver may cause relapse week , month , even year later . Therefore , P.vivax infection consider great impact morbidity mortality , result significant social economic burden . Moreover , difficult control P.vivax transmission , gametocytes appear almost simultaneously schizonts . Radical treatment infection , therefore , normally consist blood schizontocidal course chloroquine course primaquine elimination hypnozoites anti-relapse therapy . In Thailand , chloroquine primaquine remain mainstay chemotherapeutics treatment P.vivax 60 year resistance yet report . The relapse rate day 28 50 % without primaquine therapy 20 % standard primaquine therapy . Relapse observe among patient receive high dose primaquine therapy ( 30 mg daily 14 day ) . Since January 2007 , evidence reduce susceptibility Plasmodium falciparum artemisinins Western Cambodia Thai-Cambodia border first present confirmed subsequent detail pharmacokinetic-pharmacodynamic study . Nevertheless , trend gradual decline vitro sensitivity chloroquine document area country , particularly Thai-Myanmar border . There clinical-parasitological evidence chloroquine resistant P.vivax Thai-Cambodia border , Thailand . The objective present study ass vivo efficacy first line regimen chloroquine give primaquine , vitro susceptibility P.vivax isolate area along Thai-Cambodia border , Thailand .</brief_summary>
	<brief_title>Comparison Two Antimalarial Drugs Regimens Patient With Plasmodium Vivax Malaria Thailand</brief_title>
	<detailed_description>Plasmodium vivax affect 70-80 million case malaria worldwide annually , major cause human malaria part Pacific region South America . In Thailand , proportion P.vivax infection increase equal Plasmodium falciparum since 1998 . The incidence P.vivax recently report 20 per 1000 population per year . Unlike Plasmodium falciparum , P.vivax infection rarely develop complicate malaria death unusual . However , P.vivax dormant stage ( hypnozoite ) persist human liver may cause relapse week , month , even year later . Therefore , P.vivax infection consider great impact morbidity mortality , result significant social economic burden . Moreover , difficult control P.vivax transmission , gametocytes appear almost simultaneously schizonts . Radical treatment infection , therefore , normally consist blood schizontocidal course chloroquine course primaquine elimination hypnozoites antirelapse therapy . However , chloroquine-resistant P.vivax ( CRPv ) emer-ging different part world . The first report chloroquine resistant Plasmodium vivax 2 Australian soldier return Papua New Guinea Indonesia spread Asia Pacific region . In Thailand , chloroquine primaquine remain mainstay chemotherapeutics treatment P.vivax 60 year resistance yet report . Occasional failure standard primaquine therapy ( 15 mg daily 14 day ) prevent relapse observe . However , primaquine resistance confirm . In Thailand , relapse rate day 28 50 % without primaquine therapy , 20 % standard primaquine therapy . Relapse observe among patient receive high dose primaquine therapy ( 30 mg daily 14 day ) . A number factor reportedly associate relapse , reappearance P.vivax , include inadequate primaquine dosage , high parasitaemia diagnosis , short duration symptom prior diagnosis , presence gametocyte admission , age , gender . Because radical cure P.vivax hypnozoites require 14 day primaquine therapy , adherence drug regimen may greatly affect prevention relapse . Unfortunately , effect patient adherence 14 day primaquine treatment , relation prevent parasite reappearance , well-document . Since January 2007 , evidence reduce susceptibility Plasmodium falciparum artemisinins Western Cambodia Thai_Cambodia border first present confirmed subsequent detail pharmacokinetic-pharmacodynamic study . Nevertheless , trend gradual decline vitro sensitivity chloroquine document area country , particularly Thai-Myanmar border . There clinical-parasitological evidence chloroquine resistant P.vivax Thai-Cambodia border , Thailand . The objective present study ass vivo efficacy first line regimen chloroquine give primaquine , vitro susceptibility P.vivax isolate area along Thai-Cambodia border , Thailand .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Vivax</mesh_term>
	<mesh_term>Antimalarials</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>Male female , age 18 year 65 year old come study hospital follow case reinfection Acute uncomplicated malaria P.vivax infection , confirm positive blood smear asexual form P. vivax parasitaemia &gt; 1,000 parasites/microliters Fever define temperature &gt; 37.5 degree celsius history fever within last 24 hour Written inform consent Willingness ability patients/guardians comply study protocol duration study Communicate Thai language Mixed infection plasmodium specie For female : pregnancy , breast feed History allergy know contraindication chloroquine , artesunate primaquine Any criterion severe / complicate malaria ( WHO 2010 ) Presence febrile condition cause disease malaria .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>P. vivax infection</keyword>
	<keyword>Artesunate</keyword>
	<keyword>Chloroquine</keyword>
	<keyword>Primaquine</keyword>
</DOC>